Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Celiac Disease-Pipeline Review, H1 2015

Celiac Disease-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Celiac Disease-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Celiac Disease-Pipeline Review, H1 2015', provides an overview of the Celiac Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Celiac Disease

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Celiac Disease

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Celiac Disease Overview 8

Therapeutics Development 9

Pipeline Products for Celiac Disease-Overview 9

Pipeline Products for Celiac Disease-Comparative Analysis 10

Celiac Disease-Therapeutics under Development by Companies 11

Celiac Disease-Therapeutics under Investigation by Universities/Institutes 12

Celiac Disease-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Celiac Disease-Products under Development by Companies 16

Celiac Disease-Products under Investigation by Universities/Institutes 18

Celiac Disease-Companies Involved in Therapeutics Development 19

ActogeniX NV 19

Alba Therapeutics Corporation 20

Alvine Pharmaceuticals, Inc. 21

Avaxia Biologics, Inc. 22

Calypso Biotech SA 23

Dr. Falk Pharma GmbH 24

ImmusanT, Inc. 25

Provid Pharmaceuticals, Inc. 26

Sitari Pharmaceuticals, Inc. 27

Zedira GmbH 28

Celiac Disease-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

AVX-176-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Biologic to Antagonize HLA-DQ2 for Celiac Disease-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Biologic to Target Gluten and IL-10 for Celiac Disease-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Biologics to Inhibit Transglutaminase 2 for Celiac Disease-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CALY-002-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Enzyme for Celiac Disease-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Enzymes for Celiac Disease-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ERW-1041E-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

larazotide acetate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

latiglutenase-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology and Gastrointestinal Disorders-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Nexvax-2-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Nexvax-3-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Peptide for Celiac Disease-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Synthetic Peptide to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ZED-101-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

ZED-1098-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ZED-1219-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ZED-1227-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ZED-754-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Celiac Disease-Recent Pipeline Updates 60

Celiac Disease-Dormant Projects 64

Celiac Disease-Product Development Milestones 65

Featured News & Press Releases 65

Nov 19, 2014: ImmusanT's Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa's Top 10 Autoimmune/Anti-Inflammatory Projects to Watch 65

Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 65

Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 66

Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 67

Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 68

Apr 19, 2013: ImmusanT's Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 68

Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 69

Sep 04, 2012: ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease 70

May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting 71

May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

Number of Products under Development for Celiac Disease, H1 2015 9

Number of Products under Development for Celiac Disease-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Comparative Analysis by Unknown Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Products under Investigation by Universities/Institutes, H1 2015 18

Celiac Disease-Pipeline by ActogeniX NV, H1 2015 19

Celiac Disease-Pipeline by Alba Therapeutics Corporation, H1 2015 20

Celiac Disease-Pipeline by Alvine Pharmaceuticals, Inc., H1 2015 21

Celiac Disease-Pipeline by Avaxia Biologics, Inc., H1 2015 22

Celiac Disease-Pipeline by Calypso Biotech SA, H1 2015 23

Celiac Disease-Pipeline by Dr. Falk Pharma GmbH, H1 2015 24

Celiac Disease-Pipeline by ImmusanT, Inc., H1 2015 25

Celiac Disease-Pipeline by Provid Pharmaceuticals, Inc., H1 2015 26

Celiac Disease-Pipeline by Sitari Pharmaceuticals, Inc., H1 2015 27

Celiac Disease-Pipeline by Zedira GmbH, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Celiac Disease Therapeutics-Recent Pipeline Updates, H1 2015 60

Celiac Disease-Dormant Projects, H1 2015 64

List of Figures

Number of Products under Development for Celiac Disease, H1 2015 9

Number of Products under Development for Celiac Disease-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ActogeniX NV

Alba Therapeutics Corporation

Alvine Pharmaceuticals, Inc.

Avaxia Biologics, Inc.

Calypso Biotech SA

Dr. Falk Pharma GmbH

ImmusanT, Inc.

Provid Pharmaceuticals, Inc.

Sitari Pharmaceuticals, Inc.

Zedira GmbH

Celiac Disease Therapeutic Products under Development, Key Players in Celiac Disease Therapeutics, Celiac Disease Pipeline Overview, Celiac Disease Pipeline, Celiac Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com